Company profile
LAVA Therapeutics N.V.
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer
- Industry
- Biotechnology Research
- Employees
- 7
- Headquarters
- Utrecht, Utrecht
- Founded
- 2016
- LinkedIn followers
- 10,226
- Office locations
- 2
LAVA Therapeutics N.V. company summary
LAVA Therapeutics N.V. is a company in the Biotechnology Research industry, headquartered in Utrecht, Utrecht, founded in 2016. On LinkedIn the company has around 7 employees and 10,226 followers. The company lists 2 office locations. Its listed specialties include biotechnology, gamma delta T cells, bispecific antibodies, oncology.
What technology does LAVA Therapeutics N.V. use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About LAVA Therapeutics N.V.
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.
Specialties
Where is LAVA Therapeutics N.V. located?
LAVA Therapeutics N.V. lists 2 office locations.
Compare companies similar to LAVA Therapeutics N.V.
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
LAVA Therapeutics N.V. lavatherapeutics.com | Biotechnology Research | 7 | 2016 | Utrecht, Utrecht |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about LAVA Therapeutics N.V.
What does LAVA Therapeutics N.V. do?
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.
How many employees does LAVA Therapeutics N.V. have?
LAVA Therapeutics N.V. has around 7 employees on LinkedIn.
Where is LAVA Therapeutics N.V. headquartered?
LAVA Therapeutics N.V. is headquartered in Utrecht, Utrecht.
Where does LAVA Therapeutics N.V. have offices?
LAVA Therapeutics N.V. lists 2 office locations, including Utrecht, Utrecht, NL; Philadelphia, PA, US.
When was LAVA Therapeutics N.V. founded?
LAVA Therapeutics N.V. was founded in 2016.
Build a lead list from companies like LAVA Therapeutics N.V.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.